Abivax is planning to lift cash after releasing key trial information in June, its CEO informed CNBC on Tuesday, signaling to potential patrons of the agency that it’s in no rush to promote.
Intense takeover rumors have surrounded the French biotech firm for months, impacting the unstable inventory that rose almost 1,700% in 2025. Analysts see it as a chief takeover goal, and several other pharma giants have been rumored as potential patrons.
A second late-stage trial assessing the long-term, upkeep impact of Abivax’ lead, and solely, asset obefazimod will learn out late within the second quarter. Topic to optimistic information, it plans to use for U.S. Meals and Drug Administration approval within the fourth quarter, the corporate has mentioned.
The drug is broadly seen as a doubtlessly best-in-class drugs for ulcerative colitis and can be being examined as a remedy for Crohn’s illness, opening it as much as a multi-billion-dollar marketplace for Irritable Bowel Syndrome (IBS).
“It is extra logical once more, for out of doors of the U.S. to attend publish upkeep, as a result of, as you already know, the phrases are going to be higher… since we’re assured that this research goes to learn positively,” Abivax CEO Marc de Garidel mentioned, when requested about future partnerships and offers.
“Why hurry,” when the corporate is three months away from the readout, he mentioned.
Traders see the subsequent trial outcomes as a significant inflection level for the corporate and one which potential patrons are watching intently.
It’s “actually doubtless” Abivax will increase funds via a possible mixture of fairness financing and debt after the upkeep information, de Garidel mentioned. “We’re presently assessing how a lot cash we have to increase in, as an example, late June… to take us to profitability.” Funds raised can be not less than a number of million, he added.
The corporate has persistently emphasised that it has sufficient money to hold it via late 2027, and on Monday reported a money pile of 530 million euros ($613 million) as of the top of 2025. In July final yr, it raised almost $750 million shortly after one other scientific trial despatched shares up 510% in at some point.
Abivax shares have soared over the previous 12 months.
Abivax seems to be signaling to potential patrons that it’s in no rush to safe a proposal. It additionally introduced late on Monday that former Takeda Vice President Michael Nesrallah will tackle the position of chief business officer.
Its analysis and growth bills in 2025 elevated by 31.2 million euros to 177.8 million euros. Total bills will ramp up by late 2026 and 2027, largely because of business bills, de Garidel informed CNBC, additionally highlighting extra key hires on the business facet over the subsequent six months.
Biotech firms nearing launch should all the time make preparations to go at it alone with out the backing or the acquisition by a bigger peer, mentioned Van Lanschot Kempen analyst Sebastiaan van der Schoot.
“However the total assumption is that they are going to be acquired previous to approval and previous to launch,” van der Schoot mentioned, including {that a} optimistic upkeep trial readout is already largely priced in to the corporate’s share worth.
Stifel analyst Damien Choplain mentioned earlier this month that given the power of Abivax’ earlier information and the shortage of comparable belongings, he expects a deal could possibly be made forward of the upkeep information readout, even when a publish‑readout may maximize worth.
A worldwide launch is an excessive amount of for the nonetheless small firm, which presently solely has round 150 workers, mentioned de Garidel.
“After the upkeep readout, exterior of the U.S., we’ll search for a accomplice, or companions relying upon who’s and the profile of these firms, to attempt to launch exterior of the U.S,” he added.
Nonetheless, U.S. President Donald Trump’s so-called Most Favored Nation drug pricing coverage has develop into a complication as it will definitely seems to launch obefazimod exterior of the U.S. MFN refers to pegging drug costs within the U.S. to the bottom stage paid in a comparable nation.
When the corporate ultimately finds a accomplice exterior of the U.S., “we have now to remember that every thing this accomplice does exterior of the U.S. would not jeopardize what occurs within the U.S.,” de Garidel mentioned.
